Fuzzy c-mean clustering. by Janaina de Freitas Nascimento (3849415)

Map of Zimbabwe highlighting the districts detected as persistent hotspots of <i>S. haematobium</i> prevalence (PPHS), persistent hotspots of decreased praziquantel efficacy (EPHS)... by Takafira Mduluza (39754)

Boxplot of the acoustic parameters of <i>Scinax pachycrus</i> in response to wind farm noise. The graphs show that calling males found in the ponds of the most intense noise classe... by Rogério Ferreira de Oliveira (11133750)

Subjects:

Mean offspring production of the aphid population treated with different fungal isolates at a concentration of 3.2×10⁶. by Aime Cheoh Enoh (20141758)

Average difference in mean daily exercise minutes in the week before and after the specified software transition, using different minimum data thresholds. by Shelby L. Sturrock (10751675)

Subjects:

Average difference in mean daily active calories in the week before and after the specified software transition, using different minimum data thresholds. by Shelby L. Sturrock (10751675)

Subjects:

Comparison of questionnaire scores among genotypes for the significant associations. by Dai Nogimura (21445649)

Mean readiness score of modern family planning service by facility type in 2014 and 2017. by Rajon Banik (12066099)

HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. by Hakim Ben Abdallah (14578241)

Mean AIV-H9N2 shedding titer (Log₁₀) in oropharyngeal swabs. by Oumayma Arbani (21001472)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects: